Author of

• 14490

  +

  P2.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 234)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Biology, Pathology, and Molecular Testing
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 14519

    +

    P2.04-029 - Could EGFR Gene Mutations Provide a Selective Advantage to Malignant Cells in Specific Sites? New Perspectives in Lung Adenocarcinoma Biology (ID 3095)

    09:30 - 09:30  |  Author(s): G.R.R. Ricciardi
    • Abstract

    Background:
    There is growing evidence about differences in metastatic spread among distinct subsets of nonsmall cell lung cancer (NSCLC) characterized by activation of different driver oncogenes at the time of diagnosis. It is hypothesized that the dominant oncogenes in NSCLC would be associated with distinct patterns of metastatic spread. Aim of this study was to analyze the pattern of metastasization in lung adenocarcinomas according to EGFR mutational status.
    
    Methods:
    A total of 104 consecutive patients (60 M/44 F) with stage IV adenocarcinoma and an EGFR mutation (25.9%), or wild-type (74.1%) were included. We compared the incidence rates of metastatic spread at a given site between EGFR mutated and wild type. Descriptive analysis was performed on the two molecularly defined groups and associated clinical data.
    
    Results:
    37% of pts with EGFR activating mutations had bone metastases and 44% lung metastases. Moreover, BM were reported in 18%. Lung metastases were more common among pts harboring exon 19 deletions (10/12 pts). In the subgroups of EGFR wild type pts BM were present in 15%, while bone and lung metastases in 17% and 22% of pts, respectively.The difference between the incidence of metastases in the different sites according to EGFR mutational status was not statistically significant. An interesting trend toward significance was observed in the evaluation of the incidence of lung metastases in EGFR mutated pts (p=0.1).
    
    Conclusion:
    The biomolecular characteristics and the pathways involved in the different lung cancer subtypes may directly influence the metastases formation and evolution. This report underline the need to better define the clinical and molecular characteristics in adenocarcinoma subtype related to EGFR mutational status, to improve therapeutic choices and obtain relevant clinical results.